BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35081479)

  • 1. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
    Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
    Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
    Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
    Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
    Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
    Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
    Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
    J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
    Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
    Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide.
    He K; Zhang Z; Wang W; Zheng X; Wang X; Zhang X
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127167. PubMed ID: 32317208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.
    Bao SM; Hu QH; Yang WT; Wang Y; Tong YP; Bao WD
    Anticancer Agents Med Chem; 2019; 19(8):984-991. PubMed ID: 30868964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.
    Li P; Li B; Yang N; Xu T; Zheng Z
    Expert Opin Ther Pat; 2023; 33(7-8):477-492. PubMed ID: 37873645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
    J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of selective degraders of EGFR
    Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
    Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
    Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
    Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
    Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
    Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.